4D Molecular Therapeutics Inc (FDMT) Stock Price, Quote & News

Latest News on FDMT

Apr 11, 2025, 4:05 PM EDT - 9 days ago

4DMT Announces New Employment Inducement Grants

Mar 27, 2025, 8:00 AM EDT - 25 days ago

4DMT to Participate in Upcoming Investor Conferences

Mar 10, 2025, 8:00 AM EDT - 6 weeks ago

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD

Feb 28, 2025, 4:05 PM EST - 7 weeks ago

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Feb 18, 2025, 2:33 PM EST - 2 months ago

4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression

Feb 10, 2025, 10:26 AM EST - 2 months ago

Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study

Feb 8, 2025, 2:30 PM EST - 2 months ago

4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program

Nov 13, 2024, 4:05 PM EST - 5 months ago

4DMT Reports Third Quarter 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones

Nov 4, 2024, 11:00 AM EST - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Encourages Investor Participation

Nov 2, 2024, 11:00 AM EDT - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 30, 2024, 11:00 AM EDT - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 28, 2024, 11:00 AM EDT - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Investors To Take Part

Oct 18, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Encourages Investors To Help Investigate 4D Molecular Therapeutics Inc For Possible Securities Fraud

Oct 16, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Investor Participation In An Investigation Into 4D Molecular Therapeutics Inc For Securities Fraud

Oct 14, 2024, 11:00 AM EDT - 6 months ago

The Schall Law Firm Urges Investors To Help Investigate Whether 4D Molecular Therapeutics Inc Committed Securities Fraud

Oct 12, 2024, 11:00 AM EDT - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

Oct 10, 2024, 11:00 AM EDT - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Investor Participation

Oct 8, 2024, 11:00 AM EDT - 6 months ago

4D Molecular Therapeutics Inc Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 6, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Affected Investors To Reach Out

Oct 4, 2024, 12:35 PM EDT - 7 months ago

4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Oct 4, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Urges Impacted Investors To Reach Out

$Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Oct 3, 2024, 11:00 AM EDT - 7 months ago

Shareholders Are Encouraged To Join The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

Sep 30, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Possible Securities Fraud And The Schall Law Firm Invites Affected Investors To Reach Out

Sep 27, 2024, 11:00 AM EDT - 7 months ago

Shareholders Are Urged To Take Part In The Schall Law Firm's Inquiry Into 4D Molecular Therapeutics Inc For Violating Securities Laws

Sep 26, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Invites Affected Investors To Join

Sep 24, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. Is Being Investigated For Securities Fraud And Investors Are Urged To Assist The Schall Law Firm

$The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions$

Sep 23, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Invites Shareholder Participation In An Inquiry Into 4D Molecular Therapeutics Inc For Securities Related Infractions

Sep 23, 2024, 8:00 AM EDT - 7 months ago

4DMT Announces Presentation at the 2024 North American Cystic Fibrosis Conference

Sep 22, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. Is Being Looked Into For Securities Fraud And Investors With Losses Should Contact The Schall Law Firm

Sep 20, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. May Have Engaged In Securities Fraud And The Schall Law Firm Urges Investors To Join An Inquiry

Sep 18, 2024, 4:05 PM EDT - 7 months ago

4DMT Highlights Robust and Durable Clinical Activity for 4D-150 and Design of 4FRONT Phase 3 Program at 4D-150 Wet AMD Development Day

Sep 18, 2024, 11:00 AM EDT - 7 months ago

4D Molecular Therapeutics, Inc. May Have Engaged In Securities Fraud And Investors Are Urged To Join The Schall Law Firm's Inquiry

Sep 17, 2024, 11:00 AM EDT - 7 months ago

The Schall Law Firm Is Looking Into 4D Molecular Therapeutics Inc For Violating Securities Laws And Affected Shareholders Should Reach Out

Sep 17, 2024, 8:00 AM EDT - 7 months ago

Kaskela Law LLC Announces Stockholder Investigation of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) and Encourages Investors to Contact the Firm

Sep 16, 2024, 11:00 AM EDT - 7 months ago

Investors Are Invited By The Schall Law Firm To Join An Inquiry Into 4D Molecular Therapeutics, Inc.'s Possible Securities Fraud

Sep 14, 2024, 11:00 AM EDT - 7 months ago

Market Cap	141.68M
Revenue (ttm)	40,000.00
Net Income (ttm)	-160.87M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-402,175.00%
Debt to Equity Ratio	0.00

Volume	377,800
Avg Vol	843,698
Day's Range	N/A - N/A
Shares Out	46.30M
Stochastic %K	95%
Beta	2.89
Analysts	Strong Sell
Price Target	$34.40